Ticker LaunchReverse merger · Pending
Redx Pharma Limited
Reverse merger with Skye Bioscience, Inc. (SKYE)
Redx Pharma Limited agreed to merge into Skye Bioscience, Inc. (SKYE), a Nasdaq-listed biotech evaluating strategic alternatives, in a reverse merger that takes the private company public. The deal was announced on Aug 14, 2026. The combined company is expected to trade as Fibrx Therapeutics, Inc. on Nasdaq.
Fibrx Therapeutics, Inc. would be a clinical-stage fibrosis-focused company built on Redx Pharma, a UK biotech. Its lead program RXC008 is a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease, with an open US IND and FDA Fast Track designation.
- Status
- Pending
- Private company
- Redx Pharma Limited
- Public company
- Skye Bioscience, Inc. (SKYE)
- Public company business before
- Nasdaq-listed biotech evaluating strategic alternatives
- Announced
- Aug 14, 2026
- Combined company
- Fibrx Therapeutics, Inc.
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Announcement 8-K Aug 14, 2026
- Announcement press release Aug 14, 2026
- 8-K (items 1.02,5.02,8.01) Sep 11, 2026
- All filings on EDGAR CIK 1516551
Other pending reverse mergers
- North Immunology, Inc.into Aethlon Medical, Inc. · Sep 17, 2026
- Santersus AGinto Xenetic Biosciences, Inc. · Sep 16, 2026
- Ambros Therapeutics, Inc.into Werewolf Therapeutics, Inc. · Aug 21, 2026
- Slate Medicines, Inc.into Fulcrum Therapeutics, Inc. · Aug 17, 2026
- Caldera Therapeutics, Inc.into Synlogic, Inc. · Jul 29, 2026
- GH Power Inc.into Matinas BioPharma Holdings, Inc. · Jul 13, 2026